Clinical trials: Recurrent Hepatocellular Carcinoma
Hepatocellular Carcinoma, Microwave Ablation
Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
This study intends to evaluate the efficacy and safety of microwave ablation combined lenvatinib simultaneously for recurrent HCC
- Conditions
- Hepatocellular Carcinoma, Microwave Ablation, Liver Cancer, Lenvatinib
- Trial name
- NCT05444478
- Testing
- Microwave ablation, Lenvatinib
- Where
- China
- Volunteers
- 274 people
- Sponsor
- Sun Yat-sen University
Recurrent Colon Cancer, Liver Metastases
Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells.
- Conditions
- Recurrent Colon Cancer, Liver Metastases, Stage IV Rectal Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00019760
- Testing
- floxuridine, leucovorin calcium, melphalan
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Liver Transplant; Complications, Hepatocarcinoma
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
1. Explore the impact of postoperative administration of multi-kinase inhibitors (including sorafenib, lenvatinib, and regorafenib) in conjunction with bevacizumab on post-transplant recurrence, overall survival, and drug safety…
- Conditions
- Liver Transplant; Complications, Hepatocarcinoma, Recurrent Osteosarcoma, High-Risk Cancer
- Trial name
- NCT06041490
- Testing
- multi-kinase inhibitors in combination with bevacizumab
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Peking Union Medical College Hospital
Hepatocellular Carcinoma Recurrent, Surgery
Risk Factors, Prognosis, and Potential Chemoprevention Drugs in Patients With Recurrent Hepatocellular Carcinoma After Curative Surgeries: a Nationwide Retrospective Cohort Study and a Multi-center Prospective Cohort Analysis
Backgrounds: Surgeries are the mainstream of curative therapies for hepatocellular carcinoma (HCC). However, high risk of recurrent HCC after liver surgeries is still the unsolved clinical issue (early recurrence 21% per year…
- Trial name
- NCT05990959
- Testing
- No intervention for research purpose
- Where
- Taiwan
- Volunteers
- 800 people
- Sponsor
- China Medical University Hospital
Recurrent Hepatocellular Carcinoma
Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC
This is a randomized, controlled, phase 2 study to assess the efficacy and safety of ablation followed by tislelizumab versus ablation alone in patients with early recurrent hepatocellular carcinoma.
- Trial name
- NCT04663035
- Testing
- Tislelizumab, Ablation
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Ming Zhao
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
This phase II trial tests whether yttrium Y 90 glass microspheres, atezolizumab, and cabozantinib work to shrink tumors in patients with liver cancer (hepatocellular carcinoma) that cannot be removed by surgery (unresectable) or…
- Conditions
- BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma
- Trial name
- NCT05327738
- Testing
- Atezolizumab, Biopsy, Cabozantinib S-malate
- Sponsor
- OHSU Knight Cancer Institute
Male Breast Cancer, Recurrent Melanoma
Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
This pilot trial studies propranolol hydrochloride in treating patients with locally recurrent or metastatic solid tumors that cannot be removed by surgery.
- Conditions
- Male Breast Cancer, Recurrent Melanoma, Stage IV Breast Cancer, Stage IV Melanoma
- Trial name
- NCT02013492
- Testing
- propranolol hydrochloride, Correlative Studies
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- William Carson
Recurrent Hepatocellular Cancer, Chronic Liver Disease and Cirrhosis
No-touch Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma Using Triple Cooled-Wet Electrodes
To evaluate local tumor progression rate at 12 months after no-touch percutaneous radiofrequency ablation using combined energy delivery mode and triple cooled electrodes
- Trial name
- NCT05449873
- Testing
- Radiofrequency ablation using combined bipolar and monopolar energy deliver with Triple Cooled-Wet electrodes
- Where
- South Korea
- Volunteers
- 73 people
- Sponsor
- Seoul National University Hospital
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
This clinical trial studies radiolabeled glass beads (yttrium Y 90 glass microspheres) in treating patients with unresectable hepatocellular carcinoma.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT02072356
- Testing
- yttrium Y 90 glass microspheres, laboratory biomarker analysis, TheraSphere
- Where
- United States
- Volunteers
- 290 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Recurrent Hepatocellular Carcinoma
A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation
Hepatocellular carcinoma (HCC) represent approximately 70-85% of liver cancer, in which Hepatitis B virus (HBV) is the major etiologic agent accounting for at least 80% of HCC in Asian countries.
- Trial name
- NCT03634683
- Testing
- LioCyx
- Where
- 3 sites in China, Singapore
- Sponsor
- Lion TCR Pte. Ltd.
Post-orthotopic Liver Transplantation, Hepatocellular Carcinoma Recurrent
Bevacizumab Biosimilar Plus FOLFOX4 in the Treatment of Recurrent HCC After Liver Transplantation
This study is a single arm, single center, prospective and open exploratory study. About 15 patients with recurrent hepatocellular carcinoma (HCC) after liver transplantation are expected to be enrolled.Patients will be treated…
- Trial name
- NCT05355155
- Testing
- Bevacizumab Biosimilar IBI305
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Hepatocellular Carcinoma Recurrent
Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)
1. To compare systemic neoadjuvant therapy (combination of immune checkpoint inhibitors and anti-angiogenic drugs (short for "targeted-immune therapy") combined with radiofrequency ablation (RFA) and RFA alone in the treatment of…
- Trial name
- RANT (NCT05277675)
- Testing
- Tislelizumab/Sintilimab+Lenvatinib/Bevacizumab, RFA
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Southwest Hospital, China
Recurrent Hepatocellular Cancer
Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.
This study is a multi-center, prospective, single-arm, open-design phase II clinical study, mainly to explore the clinical effectiveness and safety of radiofrequency ablation combined with anti-PD-1 antibody toripalimab and…
- Trial name
- NCT05162898
- Testing
- toripalimab, Lenvatinib, Radiofrequency ablation
- Volunteers
- 90 people
- Sponsor
- Henan Cancer Hospital
Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
This phase II trial studies how well sorafenib tosylate and yttrium Y 90 glass microspheres work in treating patients with liver cancer that cannot be removed by surgery.
- Conditions
- Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Recurrent Adult Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7
- Trial name
- NCT01900002
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Sorafenib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor, Non-Small Cell Lung Cancer Recurrent
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
The main purpose of this study is to evaluate the safety, tolerability, and efficacy of the study drug known as galunisertib in combination with nivolumab in participants with advanced refractory solid tumors and in recurrent or…
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer Recurrent, Hepatocellular Carcinoma Recurrent
- Trial name
- NCT02423343
- Testing
- Galunisertib, Nivolumab
- Where
- 9 sites in United States, Spain
- Volunteers
- 41 people
- Sponsor
- Eli Lilly and Company
Hepatocellular Carcinoma Recurrent, Liver Transplant; Complications
Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence
Objective of Study: This study will evaluate the heterogeneity and evolution pathway between primary HCC and tumor relapse after liver transplant.
- Trial name
- HELP-2020 (NCT04506398)
- Testing
- liver transplant, ctDNA, whole exome sequencing
- Where
- China
- Volunteers
- 40 people
- Sponsor
- RenJi Hospital
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with advanced, unresectable, and untransplantable HCC.
- Trial name
- NCT03563170
- Testing
- ETBX-011, GI-4000, haNK for infusion
- Where
- United States
- Sponsor
- ImmunityBio, Inc.
Recurrent Hepatocellular Carcinoma
TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver Transplantation
This is a single-arm and open-label study to assess the safety, tolerability and primary efficacy of the HBV specific T cell receptor (HBV/TCR) redirected T cell in patients with recurrent Hepatitis B virus (HBV) related…
- Trial name
- NCT04677088
- Testing
- TCR-T cells
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Xiaoshun He
Recurrent Small Hepatocellular Carcinoma, Residual Small Hepatocellular Carcinoma
Comparison Between Radiofrequency Ablation and Hypofractionated Proton Beam Radiation for Recurrent/Residual HCC
This phase 3 study is to evaluate the effectiveness of the comparison between radiofrequency ablation and hypofractionated proton beam radiation.
- Trial name
- NCT01963429
- Testing
- radiofrequency ablation, Proton beam therapy
- Where
- South Korea
- Volunteers
- 144 people
- Sponsor
- National Cancer Center, Korea
Liver Transplant; Complications, Hepatocellular Carcinoma Recurrent
Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant
Objectives of Study：This study will evaluate the safety and efficacy of pembrolizumab in combination with lenvatinib as neoadjuvant therapy in participants with hepatocellular carcinoma (HCC) exceeding Milan criteria before liver…
- Trial name
- PLENTY202001 (NCT04425226)
- Testing
- Pembrolizumab Injection [Keytruda], Lenvatinib Oral Product
- Where
- China
- Volunteers
- 192 people
- Sponsor
- RenJi Hospital